Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Impact of SARS-CoV-2 vaccination in patients with vascular liver diseases: Observations from a VALDIG multicenter study

Perez-Campuzano V. et al, (2024), JHEP Reports, 6

Distinct Requirements for CD4<sup>+</sup> T Cell Help for Immune Responses Induced by mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines.

Yong L. et al, (2024), European journal of immunology

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Colton H. et al, (2024), British journal of haematology

Prospective cohort for early detection of liver cancer (Pearl): a study protocol

Khanna K. et al, (2024), BMJ Open, 14, e085541 - e085541

Corrigendum to ‘Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study’ [The Lancet Regional Health – Europe 35 (2023) 100747] (The Lancet Regional Health - Europe (2023) 35, (S2666776223001667), (10.1016/j.lanepe.2023.100747))

Evans RA. et al, (2024), The Lancet Regional Health - Europe, 44

Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom.

Garay OU. et al, (2024), Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Lim YJ. et al, (2024), British journal of haematology, 205, 440 - 451

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV.

Davis C. et al, (2024), Vaccines, 12

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS. et al, (2024), The Lancet. Rheumatology, 6, e339 - e351

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.

Hirschfield GM. et al, (2024), Hepatology communications, 8

Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery

Ali M. et al, (2024), Clinical and Experimental Immunology

Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation

Campbell C. et al, (2024), Public Health, 226, 215 - 227

Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients

Murray SM. et al, (2024), Journal of Hepatology, 80, 109 - 123

Correction to: Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies.

Gillespie IA. et al, (2023), Infectious diseases and therapy, 12, 2533 - 2534

HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.

Cargill T. et al, (2023), JHEP reports : innovation in hepatology, 5

Patient Biochemistry and Treatment Need in Chronic Hepatitis B Virus Infection Across Three Continents: Retrospective Cross-Sectional Cohort Studies

Gillespie IA. et al, (2023), Infectious Diseases and Therapy, 12, 2513 - 2532

CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study

Neale I. et al, (2023), mBio, 14

Joint statement in support of hepatitis C human challenge studies.

Alter HJ. et al, (2023), The lancet. Gastroenterology & hepatology

Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history

Hornsby H. et al, (2023), Nature Communications, 14

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?